Expert opinion
RET inhibitors are an exciting development in the fight against non-small cell lung cancer (NSCLC) and thyroid cancers. Watch our expert interviews:
- Dr Alexander Drilon discusses the impact of RET inhibitors for NSCLC
- Professor Lori Wirth introduces RET inhibitors in the management of thyroid cancers
- Professor Fernando Lopez-Rios explains molecular testing for RET alterations
RET inhibitors in non-small cell lung cancer
Dr Alexander Drilon, the Chief of the Early Drug Development Service and an Associate Attending Physician of the Thoracic Oncology Service at Memorial Sloan Kettering Cancer Center in New York City, USA, discusses RET inhibitors as a treatment for non-small cell lung cancer (NSCLC).
RET inhibitors in thyroid cancer
Professor Lori Wirth, Associate Professor of Medicine at Harvard Medical School and Medical Director of the Center for Head and Neck Cancers at Massachusetts General Hospital, Boston, USA, discusses the use of RET inhibitors to treat thyroid cancers.
Molecular testing for RET alterations
Join Professor Fernando Lopez-Rios, a professor of Pathology and Molecular Pathology from Spain, to learn why it is important to test for rearranged during transfection (RET) gene alterations in patients with non-small cell lung cancer (NSCLC) and thyroid cancer.
This content has been developed independently by Medthority who previously received educational funding in order to help provide its healthcare professional members with access to the highest quality medical and scientific information, education and associated relevant content.